A systematic review and meta-analysis of efruxifermin’s efficacy in improving liver fibrosis in patients with NASH/MASH
Background & AimsEfruxifermin is a potential treatment for non-alcoholic steatohepatitis (NASH, now termed metabolic dysfunction-associated steatohepatitis, MASH). This study aimed to analyze the effectiveness of efruxifermin in improving liver fibrosis in patients with MASH.MethodsSystematic se...
Guardat en:
| Autors principals: | , , , , , , |
|---|---|
| Format: | Artigo |
| Idioma: | Inglês |
| Publicat: |
Frontiers Media S.A.
2025-05-01
|
| Col·lecció: | Frontiers in Pharmacology |
| Matèries: | |
| Accés en línia: | https://www.frontiersin.org/articles/10.3389/fphar.2025.1594091/full |
| Etiquetes: |
Sense etiquetes, Sigues el primer a etiquetar aquest registre!
|